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Introduction 
Through a serendipitous discovery we found that ren1-CTGF transgenic mice develop 
cryoglobulinaemic glomerulonephritis(CGN). CTGF, is a matricellular protein involved in cell 
proliferation and differentiation with pleotropic effects. We previously demonstrated elevated 
serum CTGF levels in patients with HCV induced- and Mixed Essential- CV. To confirm these findings 
and investigate the therapeutic potential of targeting CTGF we used of the thymic stromal 
lymphopoeitin (TSLP) Tg mice that develop CV and CGN and targeted CTGF with antisense 
oligonucleotides (ASO).  
Methods 
CTGF levels were measured in TSLP mice and WT littermates. TSLP Tg mice were treated with weekly 
CTGF control ASO therapy or vehicle alone for 10-14 weeks.  
Results 
TSLP Tg mice show an age dependent increase in serum CTGF levels (median 1128pg/ml and 45360 
at 6 and 17 weeks respectively). With CTGF ASO this was suppressed to levels comparable to WT 
littermates(4112 pg/ml). The incidence of ulcerative ear and neck lesions was 50% lower in the CTGF 
ASO group (p=0.0549). Mice that received CTGF ASO developed significantly lower proteinuria  
compared with untreated Tg animals (p<0.001).There was less severe histological injury in the CTGF 
ASO cohort (mean mesangial expansion score 1.456±SD 0.310 vs. 2.078 ± SD 1.038, p=0.0159). WT 
mice had preserved glomerular podocyte density that was unaffected by ASO therapy (CTGF ASO 
treated 288.3 +/- 67 vs control ASO treated 285+/- 73 podocytes/106 µm3), while TSLP-Tg control 
ASO mice had significantly reduced podocyte density which was significantly ameliorated by CTGF 
ASO treatment (control ASO treated 164.8 +/- 57 vs CTGF ASO treated 218 +/- 35 podocytes/106 
µm3). The podocyte CTGF expression was also significantly lower in CTGF ASO treated mice 
compared with untreated Tg mice (proportion glomeruli with CTGF expression 0.3333 ± 0.5164 vs 
0.8333 ± 0.4082, p=0.0462 respectively). 
Conclusion 
This study demonstrates that CTGF is an important mediator of CV and CGN, and its antagonism 
provides a novel therapeutic target. The link between TSLP and CTGF is under investigation, but of 
interest is the finding that elevated TSLP levels are found in HCV patients with cryoglobulinaemia, 
suggesting that our animal data may accurately recapitulate findings in patients. 
 
 
